BioSurplus is looking to a hire a Service Technician for our South San Francisco office. The Service Technician will be responsible for servicing instruments for both BioSurplus and outside customers in the service lab and at customer sites. The Service Technician will use experience and continuous learning to perform repair, reconditioning, preventive maintenance, installation and qualification services for a wide variety of instruments used in life sciences research. He/she will be responsible for creating records for all service events performed. He/she will report to the Service Manager but will be expected to drive tasks and projects on a fairly independent basis. All work will be performed consistent with company policies and with the highest regard for safety, profitability and sensitivity to customers’ needs.
EXPERIENCE / SKILL REQUIRED
1. Minimum 3 years previous experience repairing and maintaining scientific research equipment including HPLC’s, centrifuges, microscopes, cold storage, and general lab
2. Broad-based understanding of life sciences suited to troubleshooting a wide variety of lab instruments
3. Strong computing skills: MS Windows and Office suite; cloud computing and sharing ability
4. Able to manage multiple changing priorities effectively
5. Detail and process oriented
6. Enjoys learning and deals well with a fast-paced environment and change
7. Able to work independently or on a team as needed
8. Must have a professional demeanor, appearance and strong communication skills
9. Practical, working knowledge of common desktop hardware and operating systems suitable to performing software installation, hard drive imaging and restoration
To be considered for this position, please submit resumes to email@example.com with an attached cover letter.
SAN DIEGO, Oct. 23, 2014—BioSurplus, America’s leader in used lab equipment, announced today that it will be holding a second auction of lab equipment from Lexicon Pharmaceuticals’ drug discovery and pre-clinical research facility in The Woodlands, TX. The online auction will run from October 23–30, 2014.
As Lexicon Pharmaceuticals has refocused on clinical programs, approximately 1,300 more lots of research and development equipment will be available in auction. Available lots include late-model biosafety cabinets, refrigerated centrifuges, research microscopes, vivarium equipment, behavioral studies equipment, consumables and other basic biotech equipment.
Among the lots are high-end items including:
- Applied Biosystems 3730xl Capillary Sequencer
- Labcyte Echo 550 Acoustic Nanoliter Dispenser
- Leica TCS SP5 Broadband Confocal Microscope
- Histology and pathology equipment from Leica, Shandon, and Thermo Finesse
- Upright and inverted research microscopes from Zeiss, Leica, Olympus, and Nikon
- Small animal behavioral testing equipment from Coulbourn, Accuscan, and Med Associates
- Analytical biotech equipment – flow cytometers, chromatography, imaging systems, and more
SAN DIEGO, Sept. 9, 2014—BioSurplus, America’s leader in used lab equipment, announced today that it will be holding an auction of lab equipment from Lexicon Pharmaceuticals’ drug discovery, validation and pre-clinical research facility in The Woodlands, TX. The online auction will run from October 2 – 9, 2014.
Items can be viewed on site at 8800 Technology Forest Place, The Woodlands, TX 77381-1160 on September 25 from 8 a.m. to 6 p.m, and on September 26 from 8 a.m. to 3 p.m.
As Lexicon Pharmaceuticals has refocused on clinical programs, approximately 1000 lots of research and development equipment will be available for auction. Available lots include late-model analytical balances, refrigerated centrifuges, research microscopes, spectrophotometers, vivarium equipment, consumables and other biotech basics. Included among the lots are high-end items including:
- Leica TCS SP5 Confocal Microscope
- BD FACSCanto Flow Cytometer
- GE Amersham AKTA FPLC Systems
- Olympus / Nikon / Zeiss inverted and upright microscopes
- Small animal behavioral testing equipment from Coulbourn, Accuscan, Med Associates
- Analytical chemistry equipment – HPLCs and Mass Specs from Thermo, Applied Biosystems, Waters
BioSurplus maintains cooperative partnerships with many biotech associations across the United States. Recently, our VP of National Business Development, Dawn Hocevar, gave a presentation at the Washington Biotechnology and Biomedical Association (WBBA) Purchasing Partner Luncheonoutlining the continued success BioSurplus has had in providing comprehensive purchasing and liquidation solutions for our customers. Check out the video below to learn more!
For more information on WBBA, visit their site here.
Dawn Hocevar, VP National Business Development, BioSurplus.
Last November, BioSurplus’ VP of business development, Dawn Hocevar was interviewed by Ed Miseta, chief editor of Outsourced Pharma. The piece was part of a series of interviews with women executives in the biotech and pharma industries sponsored by the organization Women In Bio (WIB).
Hocevar, in addition to her role at BioSurplus is also currently serving as WIB’s national chair of programs and development, where she works with local chapters to execute programs that promote careers, leadership and entrepreneurship for women in the life sciences.
Over her 20-plus year career, Dawn Hocevar has developed a deep knowledge of laboratory equipment and the needs of researchers and facilities managers in the industry. She got her start as a bench scientist, and went on to work for Thermo Fisher in the San Francisco Bay Area, where she was a corporate account manager and senior sales representative focusing on area biotechs and universities.
She’s been at BioSurplus for six years and has a wealth of information to share with current and future clients when it comes to buying, selling and maintaining valuable research laboratory equipment. In the Outsourced Pharma interview, she touches on some of the most important topics and best practices.
What Should Biotech Companies Look For In A Used-Equipment Supplier?
Buying used lab equipment can be a challenge. There are numerous small businesses in the market that sell equipment from their garage, warehouse or on eBay. It’s hard to tell if they’re reputable or will sell you equipment that’s in working order.
Kim Guadagno, Lt. Gov. of New Jersey, BioSurplus director of national business development Dawn Hocevar, and NJBIO president Debbie Hart, at BIO Chicago.
In the interview, Hocevar provides detailed information on what to look for in a used-equipment supplier. Among her recommendations are:
Do some research: find out how long the re-seller has been in business, and look up their Better Business Bureau rating
Make sure the company has a return policy and offers a warranty; also find out where the equipment came from—was it in a working lab, or had the equipment been in storage for many years?
Keep in mind that the purchase price might not be the full cost of the equipment you buy: Will professional installation be necessary? Will you need to purchase a software license?
What Should We Do With Our Surplus Lab Equipment? Best Practices.
Hocevar states that researchers tend to hang on to equipment they’re not using, in case they need it later. Unfortunately, the longer that equipment gathers dust in a warehouse or storeroom, the less it’s worth to another user. She recommends that companies establish a plan to regularly identify unused equipment and dispose of it quickly, while the technology is still current.
As a rule of thumb, companies should sell surplus equipment within ten years of the manufacture date. It’s also important to keep service records on hand. Customers like to know that the equipment they’re purchasing has been kept in good shape by its previous owner; equipment with this documentation will command a higher price.
Women In Bio
Stacy Silver, VP Marketing and Membership, BioFlorida; Jill Diodato, Program Manager, Banner Center for Life Science, and Dawn Hocevar, Director, National Business Development, BioSurplus. At BioFlorida 2012.
Women In Bio was founded in 2002 by Robbie Melton in the Washington, D.C. area. Melton wanted to create a forum where women in the local life sciences industry could come together and celebrate each other’s successes. The group’s footprint later expanded nationwide, and now WIB counts 11 chapters and more than 1000 members.
In the interview, Hocevar talks about the importance of WIB in the professional development of women in biotech. Its programs and events offer advice to women in all stages of their careers, from students to C-level executives. She says that one of the things she loves the most about WIB is that, “members and the women who come to the events genuinely want to connect, share their stories, and help young women explore a career in biotech.”
Although much has changed since Hocevar began her career, women are still grossly underrepresented in corporate boardrooms. In order to break through the glass ceiling, women must learn to assert themselves in the workplace; she also believes in the power of mentorship—WIB provides women with many opportunities to seek out mentors that can help them move up the corporate ladder.
Are you heading to San Diego for BIO 2014 next week? If so, do you know how you’re going to spend your free time while you’re here?
With so much to do during the conference itself, that free time just might be limited. But if you do have a chance to get away, San Diego offers some great places for you to spend it. And it’s not all about the beach and surfing….
Here we’d like to offer some of our own observations on a few of the places that make San Diego unique—and that attract millions of visitors from around the world. I’m a San Diego native myself, and would love to share some of my favorite places in the city.
Here goes (and in no particular order):
I grew up visiting Balboa Park and its many museums—in fact it’s probably my favorite place in San Diego.
Today the largest urban cultural park in the country, Balboa Park’s original 1400 acres were set aside by civic leaders in 1868. The first steps toward developing the land were taken in 1892, when the famous landscape architect Kate Sessions offered to plant 100 trees a year in exchange for space within the park to house her own commercial nursery.
Balboa Park has played host to two world’s fairs: the 1915-16 Panama California Exposition, and the 1935-36 California Pacific International Exposition. The buildings from the expositions still stand in the park, and were added to the National Register of Historic Places in 1977.
In addition to its 15 museums, the park is also home to many beautiful gardens, picnic areas, and the renowned Old Globe Theater. And if you happen to bring your kids along, don’t forget to check out the Reuben H. Fleet Science Center, with its many hands-on exhibits demonstrating the wonders of the natural world.
Koalas at the San Diego Zoo. (Photo courtesy San Diego Zoo.)
The San Diego Zoo is home to over 3,700 animals representing more than 650 species, as well as a collection of more than 700,000 exotic plants.
Established in 1916 with animals that had been on display during the Panama California Exposition, the original zoo consisted of a line of cages along Park Boulevard; its first lion cubs, Faith, Hope and Charity, were born in 1917, when a membership cost a whopping five dollars.
Memberships today are a bit more expensive, but still an incredible value. I have one myself, and visit a few times a month. One of my favorite attractions is the new Koalafornia Adventure, which opened last year.
The San Diego zoo is open every day from 9:00 AM to 6:00 PM.
Hotel del Coronada, circa 1900. Photo by William Henry Jackson.
When it opened in 1888, the Hotel del Coronado was the largest resort hotel in the world. It’s now the second-largest wooden structure in the country, and has hosted a who’s who of celebrities, including Charlie Chaplin, Betty Davis, Kirk Douglas and many more; in fact, every U.S. president since Lyndon Johnson has visited the Del.
The hotel has also served as a location for many Hollywood movies—my favorite is Some Like It Hot, the 1959 classic starring Marilyn Monroe, Tony Curtis and Jack Lemmon.
I’ve taken the San Diego harbor cruise many times over the years, and it’s still one of my favorite things to do here. It’s the perfect way to get a feel for San Diego and its harbor, from Shelter Island to the Naval Submarine Base to Coronado.
The Coronado Bridge.
One of the more interesting facts about the harbor is that in 1835, Richard Henry Dana spent a season preparing animal hides for shipment to Boston on the beach where the sub base is currently located. He tells the story of his time here, along with the rest of his two-year sea voyage in his famous book Two Years Before The Mast.
Hornblower cruises offers six daily departures from their ticket booth on Harbor Drive near the Star of India (very close to the San Diego Convention Center). Sunset happy-hour cruises are also available on Fridays and Saturdays.
UCSD – Our Biotech Hub. Scripps Aquarium, Salk Institute And More
The UCSD Geisel Library.
La Jolla is the cradle of the biotech hub here in San Diego, with the University of California, San Diego at its center. The university was established in 1960 and, along with the Scripps Institute of Oceanography, which was founded in 1903, has been a catalyst for research, innovation and the creation of new biotech companies.
There are all kinds of interesting places to visit and things to do on and around the campus. If you’re an architecture fan, you won’t want to miss the Salk Institute; the UCSD Geisel library—named for Theodore Geisel, AKA Dr. Seuss—is also instantly recognizable.
UCSD’s Birch Aquarium at the Scripps Institute is a must-see if you’re in the area, and La Jolla Shores beach next door is one of the best in the city.
Basel, Switzerland-based pharma giant Roche announced on June 2 that it has acquired Genia Technologies of Mountain View, CA, a next-gen sequencing technology company whose nanopore-based platform allows for rapid DNA sequencing using integrated circuits.
The $125 million acquisition, with a potential further payout of $225 million to investors upon completion of certain milestones, is part of Roche’s plan to develop its own sequencing platform on which it can base its diagnostic products. The company bought 454 Life Sciences, an early competitor in the sequencing technology race, in 2007, and also announced a partnership with Pacific Biosciences, another next-gen sequencing company, in September of last year.
The deal follows Roche’s failed bid for San Diego-based Illumina in 2012. Illumina, currently the leader in DNA sequencing technology with over 70% of the global sequencer market, recently broke through the $1000 price barrier for whole-genome sequencing with their new HiSeqX 10 system.
According to an article this week on Xconomy.com by Bernadette Tansey, the issue is that Illumina’s $1000 price point is only obtainable if an organization purchases a complete ten-machine bank from the company for $10 million. In other words, costs are still a major barrier to wide-scale adoption of personalized medicine.
Genia’s technology can potentially lower these costs by eliminating the need to replicate DNA, cut it up into fragments and then put it back together using expensive, heavy-duty computing power.
Instead of detecting nucleotide bases using light, Genia’s platform utilizes bioengineered nanopores, each of which can sequence an entire DNA string. In the Xconomy article, Tansey states that, “the system can be scaled up to include many thousands of those nanopores, which could enable the experimental system to sequence large amounts of DNA quickly.”
Genia will remain a standalone company under the umbrella of the Roche Sequencing Unit, which is led by Dan Zabrowski and headquartered in Pleasanton, CA. Genia’s co-founder and CEO Stefan Roever will continue to run the company with his present management team.
In order to ramp up development of the Genia platform, Roche plans to double or triple the company’s 35-person staff.
The J. Craig Venter Institute (JCVI) announced on Thursday, June 5, that it has been awarded a grant of approximately $25 million from the National Institute of Allergy and Infectious Diseases (NAID).
The funding, to be provided over a five-year period, will enable the establishment and operation of a Genome Center for Infectious Diseases (GCID). The center’s primary goal will be to further the scientific understanding of infectious diseases by focusing on the pathogens that cause them. Research results will be made available to the greater scientific community.
Infectious diseases continue to be a worldwide scourge and are one of the leading causes of death, especially among children in Southeast Asia and Africa. Malaria, for example, kills over a million people in Africa every year, and resistance to standard medications is at a crisis level. One of the new center’s focus areas will be to study pathogen drug resistance and explore new ways to fight infections by drug-resistant organisms.
The research team, to be led by JCVI co-principal investigators Karen Nelson, PhD, and William Nierman, PhD, will utilize next-generation DNA sequencing technology, along with cutting-edge bioinformatics and computer technologies, to meet the GCID’s goals. In addition to the group at the Venter Institute, 50 researchers from 40 institutions around the world will participate.
The program’s principal objective is to utilize new technologies to study pathogen biology, drug resistance, virulence, host microbiome biological interactions, and immune evasion. Three main research projects will be created, focusing on viruses, bacteria and parasites.
The J. Craig Venter Institute, which has facilities here in San Diego as well as Rockville Maryland, was created in 2006 through the merger of several affiliated research organizations. Its founder, J. Craig Venter, is a DNA sequencing pioneer, having launched Celera Genomics in 1998 with the goal of sequencing the first full human genome within a period of three years.
For the first time, researchers have used next-gen DNA sequencing to make an actionable diagnosis on a patient. A report of the case was published in an article in the New England Journal of Medicine this Wednesday, June 4.
14-year old Joshua Osborne, of Madison Wisconsin, had been placed in a medically induced coma last July due to severe swelling in his brain. When testing for multiple diseases turned up nothing, his doctor, James Gern, of the University of Wisconsin School of Medicine, reached out to two of his fellow research collaborators: Dr. Joseph DeRisi, and his colleague, pathologist Dr. Charles Chiu. Both researchers are based at the University of California, San Francisco.
DeRisi, a biochemist by training, first used a microarray for DNA sequencing in 2003 to identify the cause of the SARS virus. He and his team now employ a process called unbiased next-generation sequencing, in which they extract all DNA from a patient’s blood, spinal fluid or stool sample and then separate the fragments belonging to pathogens.
Dr. Chiu and his team have developed computer software that matches these fragments with DNA sequences available in online databases. Drs. DeRisi and Chiu combined the new sequencing method and software to identify the elusive cause of Joshua’s encephalitis: the bacteria Leptospira, which can be effectively treated with penicillin.
The entire process of sequencing, analysis, and diagnosis took 48 hours; Joshua was given high doses of penicillin and the swelling in his brain began to go down immediately after receiving treatment. He was on his feet two weeks later.
There are still many hurdles to overcome, however. The human body is teeming with microbes, and even though many of them may turn up during sequencing, their sheer numbers can make it difficult to tell which one of them is causing the problem.
San Diego-based Halozyme Therapeutics announced on Wednesday that the FDA has lifted a hold on a clinical trial of its pancreatic cancer drug, PEGPH20.
The hold on patient enrollment and dosing was put in place this April when the company, based on recommendations from an independent data monitoring committee, decided to evaluate a possible increase in the rate of thromboembolism, or blood clots, in patients treated with PEGPH20.
After reviewing data, the committee recommended last month that the trial (Study 202) be resumed under revised protocols. Patients considered to be at a high risk of thromboembolic events will be excluded from the study, and others will be given low molecular-weight heparin to help prevent blood clots.
PEGPH20 was developed through research conducted by Dr. Gregory Frost while he was at the University of California, San Francisco. While studying the extracellular matrix he discovered that tumors use hyaluronan to create a protective layer around them. Based on his findings, he went on to develop the enzyme PEGPH20, which breaks down the hyaluronan matrix.
In an article in Medscape Medical News in 2013, Dr. Frost stated:
“Nobody else is taking this approach to the cancer. When we first started, people thought we were crazy, thought we would make the tumor spread and explode. Now we are somewhere between people thinking this is crazy and thinking this is the obvious solution.” (Click here to read the article.)
He went on to say that pancreatic cancers with a high level of hyaluronan had a poorer prognosis than those that did not. When PEGPH20 is given intravenously, the hyaluronan is broken down and subsequently “liberates fluid from the tumor, pressure normalizes, reperfusion occurs, and tumor metabolism changes.”
PEGPH20 is used in combination with gemcitabine, a drug that has proven to be effective in pancreatic cancer. Gemcitabine is also used in combination with Celgene’s pancreatic cancer drug Abraxane, which I wrote about in December of last year. Click here to read the Celgene article on the BioSurplus blog.
According to Halozyme CEO, Dr. Helen Torley:
“We are committed to the development of PEGPH20 in pancreatic cancer. Halozyme worked diligently with the FDA and the DMC to develop the plan to allow the study to restart. We are pleased to be able to continue enrolling patients in this clinical program as there remains a significant need for new treatment options for pancreatic cancer patients.”